Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 315, Issue 4, 2016, Pages 371-379

  Baker, Timothy B ^a   Piper, Megan E ^a   Stein, James H ^a   Smith, Stevens S ^a   Bolt, Daniel M ^b   Fraser, David L ^a   Fiore, Michael C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; CARBON MONOXIDE; DRUG ADMINISTRATION; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; NICOTINE PATCH; NICOTINIC AGENT; VARENICLINE;

ADULT; ADVERSE EFFECTS; ARTICLE; BLOOD; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COUNSELING; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG THERAPY; DRUG TOLERABILITY; FEMALE; HEADACHE; HICCUP; HUMAN; INDIGESTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MOUTH DISEASE; NAUSEA; NICOTINE REPLACEMENT THERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCEDURES; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SELF REPORT; SMOKING; SMOKING CESSATION; SOMNOLENCE; SUBSTANCE WITHDRAWAL SYNDROME; THERAPY; TIME; TOBACCO DEPENDENCE; TREATMENT OUTCOME; UNITED STATES; URTICARIA; VIVID DREAM; VOMITING;

ADMINISTRATION AND DOSAGE; ADULT; ADVERSE EFFECTS; BLOOD; CARBON MONOXIDE; COUNSELING; DRUG THERAPY; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MEDICATION ADHERENCE; METHODS; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; OUTCOME ASSESSMENT (HEALTH CARE); SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; THERAPY; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84964253447     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.19284     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008; 57(45):1226-1228.
2. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and networkmeta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
3. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: Dept of Health and Human Services; 2008.
4. EisenbergMJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: ameta-analysis of randomized controlled trials. CMAJ. 2008;179(2):135-144.
5. Hsueh KC, Hsueh SC, Chou MY, et al. Varenicline versus transdermal nicotine patch: a 3-year follow-up in a smoking cessation clinic in Taiwan. Psychopharmacology (Berl). 2014;231(14):2819-2823.
6. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1): 56-63.
7. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32(6):664-675.
8. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66(11):1253-1262.
9. [correction published in Arch Gen Psychiatry. 2010;67(1):77].
10. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;169(22):2148-2155.
11. Zhu SH, Cummins SE, Gamst AC, Wong S, Ikeda T. Quitting smoking before and after varenicline: a population study based on two representative samples of US smokers [published online August 17, 2015]. Tob Control. doi: 10.1136/tobaccocontrol -2015-052332.
12. Fix BV, Hyland A, Rivard C, et al. Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health. 2011;8(1):222-233.
13. Ahmed AI, Ali AN, Kramers C, Harmark LV, Burger DM, Verhoeven WM. Neuropsychiatric adverse events of varenicline: a systematic review of published reports. J Clin Psychopharmacol. 2013; 33(1):55-62.
14. Mills EJ, Wu P, Lockhart I, Wilson K, Ebbert JO. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation: a systematic review and meta-analysis of one hundred and twenty studies involving 177, 390 individuals. Tob Induc Dis. 2010;8(1):8.
15. Asthana A, Piper ME, McBride PE, et al. Long-term effects of smoking and smoking cessation on exercise stress testing: three-year outcomes from a randomized clinical trial. Am Heart J. 2012;163(1):81-87.e1.
16. Stein JH, Asthana A, Smith SS, et al. Smoking cessation and the risk of diabetes mellitus and impaired fasting glucose: three-year outcomes after a quit attempt. PLoS One. 2014;9(6):e98278.
17. Catz SL, Jack LM, McClure JB, et al. Adherence to varenicline in the COMPASS smoking cessation intervention trial. Nicotine Tob Res. 2011;13(5):361-368.
18. Cooper TV, DeBonMW, Stockton M, et al. Correlates of adherence with transdermal nicotine. Addict Behav. 2004;29(8):1565-1578.
19. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613.
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9): 1119-1127.
21. Marrone GF, Shakleya DM, Scheidweiler KB, Singleton EG, Huestis MA, Heishman SJ. Relative performance of common biochemical indicators in detecting cigarette smoking. Addiction. 2011;106 (7):1325-1334.
22. Cohen J, Cohen P, West SG, Aiken LS. Applied Multiple Regression/Correlation Analysis in the Behavioral Sciences. 3rd ed. Malwah, NJ: Lawrence Erlbaum Associates; 2003.
23. Hosmer DWJ, Lemeshow SA, Sturdivant RX. Applied Logistic Regression. 3rd ed. Hoboken, NJ: Wiley; 2013.
24. Hedeker D, Mermelstein RJ, Demirtas H. Analysis of binary outcomes with missing data: missing = smoking, last observation carried forward, and a little multiple imputation. Addiction. 2007;102(10):1564-1573.
25. Heatherton TF, Kozlowski LT, Frecker RC, RickertW, Robinson J. Measuring the heaviness of smoking: using self-reported time to the first cigarette of the day and number of cigarettes smoked per day. Br J Addict. 1989;84(7):791-799.
26. Baker TB, Piper ME, McCarthy DE, et al; Transdisciplinary Tobacco Use Research Center Tobacco Dependence. Time to first cigarette in the morning as an index of ability to quit smoking: implications for nicotine dependence. Nicotine Tob Res. 2007;9(suppl 4):S555-S570.
27. Liberman JN, LichtenfeldMJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm. 2013;19(2):125-131.
28. Swan GE, McClure JB, Jack LM, et al. Behavioral counseling and varenicline treatment for smoking cessation. Am J Prev Med. 2010;38(5):482-490.
29. Centers for Disease Control and Prevention. Current cigarette smoking among adults-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61 (44):889-894.
30. Gonzales D, Rennard SI, NidesM, et al; Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55.
31. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64-71.
32. Jamal A, Agaku IT, O'Connor E, King BA, Kenemer JB, Neff L. Current cigarette smoking among adults-United States, 2005-2013. MMWR Morb Mortal Wkly Rep. 2014;63(47):1108-1112.